Jeffrey Blumer
Overview
Explore the profile of Jeffrey Blumer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
487
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nayak S, Griffiss J, Blumer J, ORiordan M, Gray W, McKenzie R, et al.
Antimicrob Agents Chemother
. 2017 Jun;
61(8).
PMID: 28584140
causes antibiotic-associated diarrhea and is a major public health concern. Current therapies disrupt the protective intestinal flora, do not reliably prevent recurrent infections, and will be decreasingly effective should less...
2.
Gonzalez D, Bradley J, Blumer J, Yogev R, Watt K, James L, et al.
Pediatr Infect Dis J
. 2017 Jan;
36(7):645-653.
PMID: 28060045
Background: Dalbavancin is a novel lipoglycopeptide antibiotic that has potent in vitro activity against Gram-positive microorganisms. Methods: We performed a phase 1, open-label, multicenter study to investigate the pharmacokinetics (PK)...
3.
Tamborlane W, Haymond M, Dunger D, Shankar R, Gubitosi-Klug R, Bethin K, et al.
Diabetes Care
. 2016 Feb;
39(3):323-9.
PMID: 26908928
No abstract available.
4.
Neely M, Blumer J
Curr Ther Res Clin Exp
. 2014 Jun;
64(2):127-36.
PMID: 24944361
Background: The pharmacokinetic characteristics of the antifungal drug caspofungin have not been reported in children. Objective: The aim of this study was to report limited caspofungin pharmacokinetic data for pediatric...
5.
Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp J, Schelonka R, Randolph D, et al.
Clin Infect Dis
. 2012 Sep;
55(11):1495-502.
PMID: 22955430
Background: Intra-abdominal infections are common in young infants and lead to significant morbidity and mortality. Meropenem is a broad-spectrum antimicrobial with excellent activity against pathogens associated with intra-abdominal infections. The...
6.
Wells T, Blowey D, Sullivan J, Blumer J, Sherbotie J, Song S, et al.
Paediatr Drugs
. 2012 Aug;
14(6):401-9.
PMID: 22880942
Background: The prevalence and importance of hypertension in younger patients is becoming increasingly recognized; however, only a limited number of clinical trials have been conducted in the pediatric population. Objective:...
7.
Redwine K, Howard L, Simpson P, Li S, Yan K, James L, et al.
Pediatr Nephrol
. 2012 May;
27(10):1937-42.
PMID: 22623022
Background: Ambulatory blood pressure monitoring (ABPM) has been proposed as a useful tool for more accurately diagnosing hypertension (HTN) and evaluating blood pressure (BP) response in pediatric anti-hypertensive trials. ABPM...
8.
Sauberan J, Bradley J, Blumer J, Stellwagen L
Pediatr Infect Dis J
. 2012 May;
31(8):832-4.
PMID: 22544050
A case is presented of a breast-feeding mother receiving meropenem treatment for a postpartum urinary tract infection caused by extended-spectrum beta-lactamase producing Escherichia coli. Five milk samples were collected in...
9.
Driscoll T, Yu L, Frangoul H, Krance R, Nemecek E, Blumer J, et al.
Antimicrob Agents Chemother
. 2011 Oct;
55(12):5770-9.
PMID: 21968355
Voriconazole pharmacokinetics are not well characterized in children despite prior studies. To assess the appropriate pediatric dosing, a study was conducted in 40 immunocompromised children aged 2 to <12 years...
10.
Driscoll T, Frangoul H, Nemecek E, Murphey D, Yu L, Blumer J, et al.
Antimicrob Agents Chemother
. 2011 Sep;
55(12):5780-9.
PMID: 21911570
The current voriconazole dosing recommendation in adolescents is based on limited efficacy and pharmacokinetic data. To confirm the appropriateness of dosing adolescents like adults, a pharmacokinetic study was conducted in...